Literature DB >> 18253926

Null mutations causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with recessive structural congenital myopathies with cores.

Nicole Monnier1, Isabelle Marty, Julien Faure, Claudia Castiglioni, Claude Desnuelle, Sabrina Sacconi, Brigitte Estournet, Ana Ferreiro, Norma Romero, Annie Laquerriere, Leila Lazaro, Jean-Jacques Martin, Eva Morava, Annick Rossi, Anneke Van der Kooi, Marianne de Visser, Corien Verschuuren, Joël Lunardi.   

Abstract

Mutations of the ryanodine receptor cause dominant and recessive forms of congenital myopathies with cores. Quantitative defects of RYR1 have been reported in families presenting with recessive forms of the disease and epigenic regulation has been recently proposed to explain potential maternal monoallelic silencing of the RYR1 gene. We investigated nine families presenting with a recessive form of the disease and showing a quantitative defect of RYR1 expression. Genetic analysis allowed the identification of a mutation on both alleles of the RYR1 gene for all patients, 15 being novel variants. We evidenced for all patients an alteration of the expression of the RYR1 gene caused by amorphic mutations responsible either for mRNA or protein instability. In seven families the variant present on the second allele was a missense mutation. In the remaining two families the second variant led to a hypomorphic expression of the RYR1 gene and was associated with a severe neonatal phenotype, pointing out the minimal amount of RYR1 needed for skeletal muscle function. Noticeably, a novel additional exon 3b was characterized in the most severely affected cases. This study showed that all cases presenting with a quantitative defect of RYR1 expression in our panel of patients affected by recessive core myopathies were caused by the presence of one recessive null allele and that variability of the phenotype depended on the nature of the mutation present on the second allele. Our study also indicated that presence of a second mutation must be investigated in sporadic cases or in dominant cases presenting with a familial clinical variability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18253926     DOI: 10.1002/humu.20696

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  30 in total

1.  Clinical utility gene card for: Multi-minicore disease.

Authors:  Suzanne Lillis; Steve Abbs; Ana Ferreiro; Francesco Muntoni; Heinz Jungbluth
Journal:  Eur J Hum Genet       Date:  2011-10-19       Impact factor: 4.246

2.  Clinical utility gene card for: Central core disease.

Authors:  Suzanne Lillis; Stephen Abbs; Clemens R Mueller; Francesco Muntoni; Heinz Jungbluth
Journal:  Eur J Hum Genet       Date:  2011-10-12       Impact factor: 4.246

3.  Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants.

Authors:  Senthilkumar Sadhasivam; Barbara W Brandom; Richard A Henker; John J McAuliffe
Journal:  Pharmacogenomics       Date:  2019-09       Impact factor: 2.533

4.  DHPR alpha1S subunit controls skeletal muscle mass and morphogenesis.

Authors:  France Piétri-Rouxel; Christel Gentil; Stéphane Vassilopoulos; Dominique Baas; Etienne Mouisel; Arnaud Ferry; Alban Vignaud; Christophe Hourdé; Isabelle Marty; Laurent Schaeffer; Thomas Voit; Luis Garcia
Journal:  EMBO J       Date:  2009-12-24       Impact factor: 11.598

5.  Bi-allelic expression of the RyR1 p.A4329D mutation decreases muscle strength in slow-twitch muscles in mice.

Authors:  Moran Elbaz; Alexis Ruiz; Sven Nicolay; Chiara Tupini; Christoph Bachmann; Jan Eckhardt; Sofia Benucci; Pawel Pelczar; Susan Treves; Francesco Zorzato
Journal:  J Biol Chem       Date:  2020-06-04       Impact factor: 5.157

6.  Exon skipping as a therapeutic strategy applied to an RYR1 mutation with pseudo-exon inclusion causing a severe core myopathy.

Authors:  John Rendu; Julie Brocard; Eric Denarier; Nicole Monnier; France Piétri-Rouxel; Cyriaque Beley; Nathalie Roux-Buisson; Brigitte Gilbert-Dussardier; Marie José Perez; Norma Romero; Luis Garcia; Joël Lunardi; Julien Fauré; Anne Fourest-Lieuvin; Isabelle Marty
Journal:  Hum Gene Ther       Date:  2013-07       Impact factor: 5.695

7.  Ca2+ dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods.

Authors:  Elena Zvaritch; Natasha Kraeva; Eric Bombardier; Robert A McCloy; Frederic Depreux; Douglas Holmyard; Alexander Kraev; Christine E Seidman; J G Seidman; A Russell Tupling; David H MacLennan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-03       Impact factor: 11.205

8.  Multi-minicore disease and atypical periodic paralysis associated with novel mutations in the skeletal muscle ryanodine receptor (RYR1) gene.

Authors:  Haiyan Zhou; Suzanne Lillis; Ryan E Loy; Farshid Ghassemi; Michael R Rose; Fiona Norwood; Kerry Mills; Safa Al-Sarraj; Russell J M Lane; Lucy Feng; Emma Matthews; Caroline A Sewry; Stephen Abbs; Stefan Buk; Michael Hanna; Susan Treves; Robert T Dirksen; Gerhard Meissner; Francesco Muntoni; Heinz Jungbluth
Journal:  Neuromuscul Disord       Date:  2010-01-18       Impact factor: 4.296

9.  Caveolin 3 is associated with the calcium release complex and is modified via in vivo triadin modification.

Authors:  Stéphane Vassilopoulos; Sarah Oddoux; Séverine Groh; Marine Cacheux; Julien Fauré; Julie Brocard; Kevin P Campbell; Isabelle Marty
Journal:  Biochemistry       Date:  2010-07-27       Impact factor: 3.162

10.  Severe congenital RYR1-associated myopathy: the expanding clinicopathologic and genetic spectrum.

Authors:  Diana Xerxes Bharucha-Goebel; Mariarita Santi; Livija Medne; Kristen Zukosky; Kristin Zukosky; Jahannaz Dastgir; Perry B Shieh; Thomas Winder; Gihan Tennekoon; Richard S Finkel; James J Dowling; Nicole Monnier; Carsten G Bönnemann
Journal:  Neurology       Date:  2013-04-03       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.